(19)
(11) EP 3 135 692 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
20.03.2019 Bulletin 2019/12

(45) Mention of the grant of the patent:
01.08.2018 Bulletin 2018/31

(21) Application number: 16187573.7

(22) Date of filing: 15.06.2011
(51) International Patent Classification (IPC): 
C12N 5/10(2006.01)
C12N 15/62(2006.01)
C12N 15/86(2006.01)
C07K 16/18(2006.01)
G01N 33/574(2006.01)
G01N 33/577(2006.01)
 C12N 15/09(2006.01)
C12N 15/82(2006.01)
A61K 47/68(2017.01)
C07K 16/30(2006.01)
A61K 39/00(2006.01)

(54)

ANTIBODIES TO ENDOPLASMIN AND THEIR USE

ANTIKÖRPER ZU ENDOPLASMIN UND DEREN VERWENDUNG

ANTICORPS DIRIGÉS CONTRE L'ENDOPLASMINE ET LEUR UTILISATION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 16.06.2010 US 355516 P

(43) Date of publication of application:
01.03.2017 Bulletin 2017/09

(62) Application number of the earlier application in accordance with Art. 76 EPC:
11796394.2 / 2582727

(73) Proprietor: University of Pittsburgh - Of the Commonwealth System of Higher Education
Pittsburgh, PA 15260 (US)

(72) Inventors:
  • FERRONE, Soldano
    Boston, MA 02108 (US)
  • WANG, Xinhui
    Boston, MA 02135 (US)
  • CONRADS, Thomas P.
    Reston, VA 20191 (US)
  • FAVOINO, Elvira
    Casamassima BA 70010 (IT)
  • HOOD, Brian
    Reston, VA 20191 (US)

(74) Representative: Gowshall, Jonathan Vallance 
Forresters IP LLP Skygarden Erika-Mann-Strasse 11
80636 München
80636 München (DE)


(56) References cited: : 
WO-A1-2009/039409
WO-A1-2012/075324
US-A1- 2004 001 789
 WO-A1-2009/113074
WO-A2-2006/120230
US-A1- 2005 008 649
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).